| Condition |
Trial Name |
Sponsor |
| Solid |
1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors |
Boehringer Ingelheim |
| Solid Tumors |
1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors |
Mirati Therapeutics, Inc. |
| Rectal Cancer |
19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma |
Memorial Sloan Kettering Cancer Center |
| Breast Cancer |
ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer |
Gilead Sciences |
| Breast Cancer |
ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer |
Gilead Sciences |
| Cachexia in Colorectal or Pancreatic Cancer |
AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy |
AVEO Pharmaceuticals, Inc. |
| Solid Tumors |
BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors |
Boehringer Ingelheim |
| Non-Small Cell Lung Cancer |
BI 1479-0001: Anti-HER2 TKI BI 1810631 for the Treatment of HER2 Mutant NSCLC |
Boehringer Ingelheim |
| Breast Cancer |
BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy |
BriaCell Therapeutics Corporation |
| Dedifferentiated Liposarcoma |
Brightline-1: MDM2 Inhibitor BI 907828 for the First Line Treatment of MDM2-Mutant Advanced or Metastatic Dedifferentiated Liposarcoma |
Boehringer Ingelheim |
| Biliary Tract Cancer, Pancreatic Cancer |
Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer |
Boehringer Ingelheim |
| Breast Cancer |
CDK2/4/6 Inhibitor RGT-419B in HR-Positive, HER2-Negative Metastatic Breast Cancer |
Regor Pharmaceuticals, Inc. |
| Solid Tumor or Lymphoma |
CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
CStone Pharmaceuticals |
| Solid Tumors |
DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors |
Day One Biopharmaceuticals, Inc. |
| Breast Cancer |
DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer |
AstraZeneca |
| Solid Tumors |
ENV-ONC-101: Hedgehog Pathway Inhibitor in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsTaladegib |
Endeavor Biomedicines, Inc. |
| Central Nervous System Cancer |
F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy |
Fore Biotherapeutics |
| Solid Tumors |
F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors |
Fore Biotherapeutics |
| Colon or Rectal Cancer |
GO-010: Neoantigen Vaccine GRT-C901/GRT-R902 as Maintenance After First Line Metastatic Therapy |
Gritstone bio, Inc. |
| Head and Neck Squamous Cell Carcinoma |
GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC |
Gilead Sciences, Inc. |
| Non-Small Cell Lung Cancer |
HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma |
Lantern Pharma Inc. |
| Colon or Rectal Cancer |
KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer |
Mirati Therapeutics, Inc. |
| Solid Tumors |
KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors |
Mirati Therapeutics Inc. |
| Non-Small Cell Lung Cancer |
KRYSTAL-7: Adagrasib Monotherapy or in Combination With Pembrolizumab as First Line Treatment for KRAS G12C Mutant NSCLC |
Mirati Therapeutics Inc. |
| Diffuse Large B-Cell Lymphoma |
LOTIS-9: Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients |
ADC Therapeutics SA |
| Colon or Rectal Cancer |
LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash |
Lutris Pharma Ltd. |
| Solid Tumors |
MANTRA-2: Milademetan for the Treatment of MDM2 Amplified Solid Tumors |
Rain Oncology Inc |
| Non-Hodgkin Lymphoma |
MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies |
Genentech, Inc. |
| Hyperkalemia/Chronic Kidney Disease |
NYH-01: Hyperkalemia/Chronic Kidney Disease |
Relypsa |
| Solid Tumors |
OnTARGET: Crofelemer for Diarrhea Prophylaxis in Patients Receiving Targeted Therapy |
Napo Pharmaceuticals |
| Solid Tumors |
PBI-200-101: TRK Inhibitor PBI-200 in NTRK Fusion Positive or NTRK Amplified Solid Tumor |
Pyramid Biosciences |
| Colorectal Cancer |
PORCUPINE: PORCN Inhibitor RXC004 Alone or in Combination with Nivolumab for Microsatellite Stable RNF43 or RSPO Altered Metastatic Colorectal Cancer |
Redx Pharma Plc |
| Solid Tumors |
PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor |
Aadi Bioscience, Inc. |
| Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome |
PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndrome |
Prelude Therapeutics |
| Solid Tumors |
REFOCUS: RLY-4408 in FGFR2-Altered Solid Tumors |
Relay Therapeutics |
| Breast Cancer |
SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression |
AstraZeneca |
| Solid Tumors |
SPARTA: c-MET Inhibitor APL-101 for Patients with c-MET Altered Solid Tumors |
Apollomics Inc. |
| Multiple Myeloma |
TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma |
Takeda Development Center Americas, Inc |
| Solid Tumors |
TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study |
Hoffmann-La Roche |
| Breast Cancer |
[Registry] Liquid vs Tissue Biopsy Concordance in Samples of 1st Suspected Breast Cancer Recurrence & Metastasis |
Epic Sciences |
| Cancer Diagnosis |
[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients |
Memorial Sloan Kettering Cancer Center |
| Various Indications |
[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) |
Precision for Medicine |
| Solid Tumors |
[Sample Collection] Collection and Distribution of Biofluids for Research Purposes |
Bluestar Genomics |
| Solid Tumors |
[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) |
Exact Sciences Thrive LLC |
| Various Indications |
[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) |
MT Group |
| Various Indications |
[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) |
SERATRIALS, LLC. |
| Solid Tumors |
[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening |
Freenome Holdings Inc. |
| Solid Tumors |
eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion |
Merus N.V. |
